Drug
Margetuximab
Margetuximab: highest development phase Phase 3, developed by MacroGenics, Zai Lab. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- MacroGenics, Zai Lab
Trials
| Drug | Phase | Indication |
|---|---|---|
| Margetuximab NCT02492711 | Phase 3 | HER-2 Positive Breast Cancer |
| margetuximab NCT04082364 | Phase 2/3 | Gastric Cancer |
| Margetuximab NCT04262804 | Phase 2 | Breast Cancer Metastatic |
| Margetuximab NCT05227131 | Phase 2 | Metastatic Breast Cancer |
| margetuximab NCT01148849 | Phase 1 | Breast Cancer |
Latest
No recent events.
Follow Margetuximab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.